Impact of V9302, a competitive antagonist of transmembrane glutamine flux on reversal of resistance in breast cancer cell lines
Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years Real-world, integrated data follows-up on previous insights, analytics
Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials
At 48 weeks with the 12 mg dose, 100% of participants achieved at least 5% weight reduction, 93% achieved at least 10% reduction, and 83% achieved 15% or greater reductionthresholds associated with significant health improvements
First, tissues must increase the fraction of energy they derive from fat
This is a drug interaction that directly contributes to fatigue in people on combination therapy